The immune regulation in cancer by the amino acid metabolizing enzymes ARG and IDO

Current Opinion in Pharmacology

Volumn 35, Issue , 2017, Pages 30-39

  Mondanelli, Giada ^a   Ugel, Stefano ^b   Grohmann, Ursula ^a   Bronte, Vincenzo ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO N (3 CHLORO 4 FLUOROPHENYL) N' HYDROXY 1,2,5 OXADIAZOLE 3 CARBOXIMIDAMIDE; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ARGINASE; ARGINASE INHIBITOR; ARGININE; CB 1158; DEXAMETHASONE; DOCETAXEL; EPACADOSTAT; GDC 0919; HYDROLASE INHIBITOR; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; INDOXIMOD; IPILIMUMAB; LENALIDOMIDE; N(G) HYDROXYARGININE; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; PF 06840003; PNEUMOCOCCUS VACCINE; S (2 BORONOETHYL)CYSTEINE HYDROCHLORIDE; SILDENAFIL; TADALAFIL; TAMOXIFEN; TERGENPUMATUCEL L; TRYPTOPHAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; [3 (AMINOCARBONYL)FUROXAN 4YL]METHYLSALICYLIC ACID; TRANSFORMING GROWTH FACTOR BETA;

ACUTE MYELOID LEUKEMIA; ADOPTIVE TRANSFER; AMINO ACID METABOLISM; ANTINEOPLASTIC ACTIVITY; ASTROCYTOMA; ATHEROSCLEROSIS; BRAIN CANCER; BREAST CANCER; CANCER IMMUNOTHERAPY; COLORECTAL CANCER; DRUG STRUCTURE; ENDOTHELIAL DYSFUNCTION; ENZYME DEGRADATION; GENITAL TRACT CANCER; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREGULATION; MALIGNANT NEOPLASM; MAMMAL; MELANOMA; METASTATIC BREAST CANCER; METASTATIC MELANOMA; MOLECULAR INTERACTION; MOLECULAR RECOGNITION; MULTIPLE MYELOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; OLIGODENDROGLIOMA; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; REPERFUSION INJURY; REVIEW; T LYMPHOCYTE; TRANSITIONAL CELL CARCINOMA; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UNSPECIFIED SIDE EFFECT; ANIMAL; DENDRITIC CELL; IMMUNOLOGY; METABOLISM; NEOPLASM;

ANIMALS; ARGINASE; DENDRITIC CELLS; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA; TRYPTOPHAN; TUMOR MICROENVIRONMENT;

EID: 85019951577     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2017.05.002     Document Type: Review

References (64)

1. Brahmer, J., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373 (2015), 123–135.
2. Grohmann, U., Bronte, V., Control of immune response by amino acid metabolism. Immunol. Rev. 236 (2010), 243–264.
3. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
4. Vander Heiden, M.G., Cantley, L.C., Thompson, C.B., Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324 (2009), 1029–1033.
5. Geiger, R., et al. L-arginine modulates T. cell metabolism and enhances survival and anti-tumor activity. Cell, 167, 2016 p. 829–842.e13 This is the first work demonstrating that L-arginine plays a crucial control of metabolic fitness, survival capacity, and anti-tumor activity of central memory T cells.
6. Rodriguez, P.C., et al. L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J. Immunol. 171 (2003), 1232–1239.
7. Rodriguez, P.C., Quiceno, D.G., Ochoa, A.C., L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 109 (2007), 1568–1573.
8. Jenkinson, C.P., Grody, W.W., Cederbaum, S.D., Comparative properties of arginases. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 114 (1996), 107–132.
9. Morris, S.M. Jr., Regulation of enzymes of the urea cycle and arginine metabolism. Annu. Rev. Nutr. 22 (2002), 87–105.
10. Kim, P.S., et al. Expression of the liver form of arginase in erythrocytes. Mol. Genet. Metab. 76 (2002), 100–110.
11. Jacobsen, L.C., et al. Arginase 1 is expressed in myelocytes/metamyelocytes and localized in gelatinase granules of human neutrophils. Blood 109 (2007), 3084–3087.
12. Rotondo, R., et al. Exocytosis of azurophil and arginase 1-containing granules by activated polymorphonuclear neutrophils is required to inhibit T lymphocyte proliferation. J. Leukoc. Biol. 89 (2011), 721–727.
13. Monticelli, L.A., et al. Arginase 1 is an innate lymphoid-cell-intrinsic metabolic checkpoint controlling type 2 inflammation. Nat. Immunol. 17 (2016), 656–665.
14. Dzik, J.M., Evolutionary roots of arginase expression and regulation. Front. Immunol., 5, 2014, 544.
15. Hackett, C.S., et al. Expression quantitative trait loci and receptor pharmacology implicate Arg1 and the GABA-A receptor as therapeutic targets in neuroblastoma. Cell Rep. 9 (2014), 1034–1046.
16. Elahi, S., et al. Immunosuppressive CD71+ erythroid cells compromise neonatal host defence against infection. Nature 504 (2013), 158–162.
17. Porembska, Z., et al. Arginase in patients with breast cancer. Clin. Chim. Acta 328 (2003), 105–111.
18. Wu, C.W., et al. Serum arginase level in patients with gastric cancer. J. Clin. Gastroenterol. 18 (1994), 84–85.
19. Bronte, V., et al. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J. Exp. Med. 201 (2005), 1257–1268.
20. Mussai, F., et al. Neuroblastoma arginase activity creates an immunosuppressive microenvironment that impairs autologous and engineered immunity. Cancer Res. 75 (2015), 3043–3053.
21. Mussai, F., et al. Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. Blood 122 (2013), 749–758.
22. Ino, Y., et al. Arginase II. expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer. PLoS One, 8, 2013, e55146.
23. Ugel, S., et al. Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J. Clin. Invest. 125 (2015), 3365–3376.
24. Bronte, V., Zanovello, P., Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 5 (2005), 641–654.
25. Marvel, D., Gabrilovich, D.I., Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J. Clin. Invest. 125 (2015), 3356–3364.
26. Nagaraj, S., et al. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J. Immunol. 184 (2010), 3106–3116.
27. Molon, B., et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J. Exp. Med. 208 (2011), 1949–1962.
28. De Sanctis, F., et al. The emerging immunological role of post-translational modifications by reactive nitrogen species in cancer microenvironment. Front. Immunol., 5, 2014, 69.
29. Marigo, I., et al. T cell cancer therapy requires CD40-CD40L activation of tumor necrosis factor and inducible nitric-oxide-synthase-producing dendritic cells. Cancer Cell 30 (2016), 377–390 This work highlights, for the first time, ARG1 has a hierarchical negative role when compared to NOS2 in creating a tumor-derived immunosuppressive environment.
30. Pico de Coana, Y., et al. Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production. Cancer Immunol. Res. 1 (2013), 158–162.
31. Grohmann, U., Fallarino, F., Puccetti, P., Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol. 24 (2003), 242–248.
32. Puccetti, P., Grohmann, U., IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Nat. Rev. Immunol. 7 (2007), 817–823.
33. van Baren, N., Van den Eynde, B.J., Tryptophan-degrading enzymes in tumoral immune resistance. Front. Immunol., 6, 2015, 34.
34. Kennedy, B.E., et al. NAD+ salvage pathway in cancer metabolism and therapy. Pharmacol. Res. 114 (2016), 274–283.
35. Merlo, L.M., Mandik-Nayak, L., IDO2: a pathogenic mediator of inflammatory autoimmunity. Clin. Med. Insights Pathol. 9 (2016), 21–28.
36. Fallarino, F., et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J. Immunol. 176 (2006), 6752–6761.
37. Platten, M., Wick, W., Van den Eynde, B.J., Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res. 72 (2012), 5435–5440.
38. Bessede, A., et al. Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature 511 (2014), 184–190.
39. Grohmann, U., Puccetti, P., The coevolution of IDO1 and AhR in the emergence of regulatory T-cells in mammals. Front. Immunol., 6, 2015, 58.
40. Orabona, C., Pallotta, M.T., Grohmann, U., Different partners, opposite outcomes: a new perspective of the immunobiology of indoleamine 2,3-dioxygenase. Mol. Med. 18 (2012), 834–842.
41. Orabona, C., et al. SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 20828–20833 This work demonstrated the occurrence of regulatory proteloysis occurring to IDO1 in DCs exposed to inflammatory signals.
42. Orabona, C., Grohmann, U., Indoleamine 2,3-dioxygenase and regulatory function: tryptophan starvation and beyond. Methods Mol. Biol. 677 (2011), 269–280.
43. Albini, E., et al. Distinct roles of immunoreceptor tyrosine-based motifs in immunosuppressive indoleamine 2,3-dioxygenase 1. J. Cell Mol. Med. 21 (2017), 165–176.
44. Belladonna, M.L., et al. Cutting edge: autocrine TGF-beta sustains default tolerogenesis by IDO-competent dendritic cells. J. Immunol. 181 (2008), 5194–5198.
45. Boutard, V., et al. Transforming growth factor-beta stimulates arginase activity in macrophages: implications for the regulation of macrophage cytotoxicity. J. Immunol. 155 (1995), 2077–2084.
46. Mondanelli, G., et al. A relay pathway between arginine and tryptophan metabolism confers immunosuppressive properties on dendritic cells. Immunity 46 (2017), 233–244 This work highlights, for the first time, an immunosuppressive, entwined pathway between TGF-β, Arg1, and iDO1.
47. Pallotta, M.T., et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat. Immunol. 12 (2011), 870–878.
48. Holtta, E., Auvinen, M., Andersson, L.C., Polyamines are essential for cell transformation by pp60v-src: delineation of molecular events relevant for the transformed phenotype. J. Cell Biol. 122 (1993), 903–914.
49. Godin-Ethier, J., et al. Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin. Cancer Res. 17 (2011), 6985–6991.
50. Gannon, P.O., et al. Androgen-regulated expression of arginase 1, arginase 2 and interleukin-8 in human prostate cancer. PLoS One, 5, 2010, e12107.
51. Bronte, V., et al. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J. Immunol. 170 (2003), 270–278.
52. Uyttenhove, C., et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9 (2003), 1269–1274.
53. Rodriguez, P.C., et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 64 (2004), 5839–5849.
54. Lorvik, K.B., et al. Adoptive transfer of tumor-specific Th2 cells eradicates tumors by triggering an in situ inflammatory immune response. Cancer Res. 76 (2016), 6864–6876.
55. De Santo, C., et al. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 4185–4190.
56. Serafini, P., et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med. 203 (2006), 2691–2702.
57. Works, M., et al. Immuno-oncology agent CB-1158 is a potent and selective arginase inhibitor and causes an immune-mediated anti-tumor response. Cancer Res., 76, 2016.
58. Lob, S., et al. Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood 111 (2008), 2152–2154.
59. Hou, D.Y., et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res. 67 (2007), 792–801.
60. Jochems, C., et al. The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells. Oncotarget 7 (2016), 37762–37772.
61. Liu, X., et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 115 (2010), 3520–3530.
62. Gibney, G., et al. Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma. Eur. J. Cancer 51 (2015), S106–S107.
63. Grohmann, U., et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 3 (2002), 1097–1101.
64. Tumang, J., et al. Abstract 4863: PF-06840003: a highly selective IDO-1 inhibitor that shows good in vivo efficacy in combination with immune checkpoint inhibitors. Cancer Res., 76, 2016, 4863.